
ENALAPRIL MALEATE- enalapril maleate tablet ENALAPRIL MALEATE- enalapril maleate tablet Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.

Rx only

DESCRIPTION

Enalapril Maleate Tablets, USP is the maleate salt of enalapril, the ethyl ester of a longacting angiotensin converting enzyme inhibitor, enalaprilat. Enalapril maleate is chemically described as (S)-1- [*N*-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline, (*Z*)-2butenedioate salt (1:1). Its empirical formula is C20H28N2O5•C4H4O4, and its structural formula is:



Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.53. It is sparingly soluble in water, soluble in ethanol, and freely soluble in methanol.

Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin-converting enzyme inhibitor.

Enalapril Maleate Tablets, USP are supplied as 2.5 mg, 5 mg, 10 mg, and 20 mg tablets for oral administration. In addition to the active ingredient enalapril maleate, each tablet contains the following inactive ingredients: corn starch, lactose monohydrate, magnesium stearate, pregelatinized starch, and sodium bicarbonate. Each 2.5 mg tablet contains D&C red #27 aluminum lake, D&C yellow #10 aluminum lake, FD&C blue #1 aluminum lake, FD&C red #40 aluminum lake, and FD&C yellow #6 aluminum lake. Each 10 mg tablet contains FD&C blue #2 aluminum lake, FD&C red #40 aluminum lake and FD&C yellow #6 aluminum lake. Each 20 mg tablet contains FD&C yellow #6 aluminum lake.

CLINICAL PHARMACOLOGY

Mechanism of Action

Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Although the latter decrease is small, it results in small increases of serum potassium. In hypertensive patients treated with Enalapril Maleate Tablets, USP alone for up to 48 weeks, mean increases in serum potassium of approximately 0.2 mEq/L were observed. In patients treated with enalapril maleate plus a thiazide diuretic, there was essentially no change in serum potassium (see **PRECAUTIONS**). Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity.

ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of enalapril maleate remains to be elucidated.

While the mechanism through which enalapril maleate lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, enalapril maleate is antihypertensive even in patients with low-renin hypertension. Although Enalapril Maleate Tablets, USP was antihypertensive in all races studied, black hypertensive patients (usually a low-renin hypertensive population) had a smaller average response to enalapril monotherapy than non-black patients.

Pharmacokinetics and Metabolism

Following oral administration of enalapril maleate, peak serum concentrations of enalapril occur within about one hour. Based on urinary recovery, the extent of absorption of enalapril is approximately 60 percent. Enalapril absorption is not influenced by the presence of food in the gastrointestinal tract. Following absorption, enalapril is hydrolyzed to enalaprilat, which is a more potent angiotensin-converting enzyme inhibitor than enalapril; enalaprilat is poorly absorbed when administered orally. Peak serum concentrations of enalaprilat occur three to four hours after an oral dose of enalapril maleate. Excretion of enalapril maleate is primarily renal. Approximately 94 percent of the dose is recovered in the urine and feces as enalaprilat or enalapril. The principal components in urine are enalaprilat, accounting for about 40 percent of the dose and intact enalapril. There is no evidence of metabolites of enalapril, other than enalaprilat.

The serum concentration profile of enalaprilat exhibits a prolonged terminal phase, apparently representing a small fraction of the administered dose that has been bound to ACE. The amount bound does not increase with dose, indicating a saturable site of binding. The effective half-life for accumulation of enalaprilat following multiple doses of enalapril maleate is 11 hours. The disposition of enalapril and enalaprilat in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. With glomerular filtration rate \leq 30 mL/min, peak and trough enalaprilat levels increase, time to peak concentration increases and time to steady state may be delayed. The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of renal insufficiency (see **DOSAGE AND ADMINISTRATION**). Enalaprilat is dialyzable at the rate of 62 mL/min.

Studies in dogs indicate that enalapril crosses the blood-brain barrier poorly, if at all; enalaprilat does not enter the brain. Multiple doses of enalapril maleate in rats do not result in accumulation in any tissues.

Milk of lactating rats contains radioactivity following administration of ¹⁴C-enalapril

maleate. Radioactivity was found to cross the placenta following administration of labeled drug to pregnant hamsters.

Pharmacodynamics and Clinical Effects

Hypertension

Administration of enalapril maleate to patients with hypertension of severity ranging from mild to severe results in a reduction of both supine and standing blood pressure usually with no orthostatic component. Symptomatic postural hypotension is therefore infrequent, although it might be anticipated in volume-depleted patients (see **WARNINGS, Hypotension**).

In most patients studied, after oral administration of a single dose of enalapril, onset of antihypertensive activity was seen at one hour with peak reduction of blood pressure achieved by four to six hours.

At recommended doses, antihypertensive effects have been maintained for at least 24 hours. In some patients the effects may diminish toward the end of the dosing interval (**see DOSAGE AND ADMINISTRATION, Hypertension**).

In some patients achievement of optimal blood pressure reduction may require several weeks of therapy.

The antihypertensive effects of enalapril maleate have continued during long-term therapy. Abrupt withdrawal of enalapril maleate has not been associated with a rapid increase in blood pressure.

In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with an increase in cardiac output and little or no change in heart rate. Following administration of enalapril maleate, there is an increase in renal blood flow glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with renovascular hypertension.

When given together with thiazide-type diuretics, the blood pressure lowering effects of enalapril maleate are approximately additive.

In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate (see **PRECAUTIONS, Drug Interactions**).

<u>Heart Failure</u>

In trials in patients treated with digitalis and diuretics, treatment with enalapril resulted in decreased systemic vascular resistance, blood pressure, pulmonary capillary wedge pressure and heart size, and increased cardiac output and exercise tolerance. Heart rate was unchanged or slightly reduced, and mean ejection fraction was unchanged or increased. There was a beneficial effect on severity of heart failure as measured by the New York Heart Association (NYHA) classification and on symptoms of dyspnea and fatigue. Hemodynamic effects were observed after the first dose and appeared to be maintained in uncontrolled studies lasting as long as four months. Effects on exercise tolerance, heart size, and severity and symptoms of heart failure were observed in placebo-controlled studies lasting from eight weeks to over one year.

Heart Failure, Mortality Trials

In a multicenter, placebo-controlled clinical trial, 2,569 patients with all degrees of symptomatic heart failure and ejection fraction \leq 35 percent were randomized to placebo or enalapril and followed for up to 55 months (SOLVD-Treatment). Use of enalapril was associated with an 11 percent reduction in all-cause mortality and a 30 percent reduction in hospitalization for heart failure. Diseases that excluded patients from enrollment in the study included severe stable angina (>2 attacks/day), hemodynamically significant valvular or outflow tract obstruction, renal failure (creatinine >2.5 mg/dL), cerebrovascular disease (e.g., significant carotid artery disease), advanced pulmonary disease, malignancies, active myocarditis and constrictive pericarditis. The mortality benefit associated with enalapril does not appear to depend upon digitalis being present.

A second multicenter trial used the SOLVD protocol for study of asymptomatic or minimally symptomatic patients. SOLVD-Prevention patients, who had left ventricular ejection fraction \leq 35% and no history of symptomatic heart failure, were randomized to placebo (n=2117) or enalapril (n=2111) and followed for up to 5 years. The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in 80 percent of patients, current angina pectoris in 34 percent, and a history of hypertension in 37 percent. No statistically significant mortality effect was demonstrated in this population. Enalapril-treated subjects had 32% fewer first hospitalizations for heart failure, and 32% fewer total heart failure hospitalizations. Compared to placebo, 32 percent fewer patients receiving enalapril developed symptoms of overt heart failure. Hospitalizations for cardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group (for enalapril vs. placebo, respectively, 1166 vs. 1201 first hospitalizations, 2649 vs. 2840 total hospitalizations), although the study was not powered to look for such an effect.

The SOLVD-Prevention trial was not designed to determine whether treatment of asymptomatic patients with low ejection fraction would be superior, with respect to preventing hospitalization, to closer follow-up and use of enalapril at the earliest sign of heart failure. However, under the conditions of follow-up in the SOLVD-Prevention trial (every 4 months at the study clinic; personal physician as needed), 68% of patients on placebo who were hospitalized for heart failure had no prior symptoms recorded which would have signaled initiation of treatment.

The SOLVD-Prevention trial was also not designed to show whether enalapril modified the progression of underlying heart disease.

In another multicenter, placebo-controlled trial (CONSENSUS) limited to patients with NYHA Class IV congestive heart failure and radiographic evidence of cardiomegaly, use of enalapril was associated with improved survival. The results are shown in the following table.

	SURVIVAL (%)		
	Six Months	One Year	
Enalapril maleate (n=127)	74	64	
Placebo (n=126)	56	48	

In both CONSENSUS and SOLVD-Treatment trials, patients were also usually receiving

digitalis, diuretics or both.

Clinical Pharmacology in Pediatric Patients

A multiple dose pharmacokinetic study was conducted in 40 hypertensive male and female pediatric patients aged 2 months to \leq 16 years following daily oral administration of 0.07 to 0.14 mg/kg enalapril maleate. At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.

Conversion of enalapril to enalaprilat was in the range of 63-76%. The overall results of this study indicate that the pharmacokinetics of enalapril in hypertensive children aged 2 months to ≤ 16 years are consistent across the studied age groups and consistent with pharmacokinetic historic data in healthy adults.

In a clinical study involving 110 hypertensive pediatric patients 6 to 16 years of age, patients who weighed <50 kg received either 0.625, 2.5 or 20 mg of enalapril daily and patients who weighed ≥50 kg received either 1.25, 5, or 40 mg of enalapril daily. Enalapril administered once daily lowered trough blood pressure in a dose-dependent manner. The dose-dependent antihypertensive efficacy of enalapril was consistent across all subgroups (age, Tanner stage, gender, race). However, the lowest doses studied, 0.625 mg and 1.25 mg, corresponding to an average of 0.02 mg/kg once daily, did not appear to offer consistent antihypertensive efficacy. In this study, enalapril maleate was generally well tolerated.

In the above pediatric studies, enalapril maleate was given as tablets and for those children and infants who were unable to swallow tablets or who required a lower dose than is available in tablet form, enalapril was administered in a suspension formulation (see **DOSAGE AND ADMINISTRATION, Preparation of Suspension**).

INDICATIONS AND USAGE

Hypertension

Enalapril maleate tablets USP are indicated for the treatment of hypertension.

Enalapril maleate tablets USP are effective alone or in combination with other antihypertensive agents, especially thiazide- type diuretics. The blood pressure lowering effects of enalapril maleate tablets USP and thiazides are approximately additive.

Heart Failure

Enalapril maleate tablets USP are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate tablets USP improves symptoms, increases survival, and decreases the frequency of hospitalization (see **CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials** for details and limitations of survival trials).

Asymptomatic Left Ventricular Dysfunction

In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction \leq 35 percent), enalapril maleate tablets USP decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see **CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials** for details and limitations of survival trials).

In using enalapril maleate tablets USP consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate tablets USP does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis).

In considering use of enalapril maleate tablets USP, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see **WARNINGS, Head and Neck Angioedema**).

CONTRAINDICATIONS

Enalapril maleate is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema.

Do not coadminister aliskiren with enalapril maleate in patients with diabetes (see **PRECAUTIONS, Drug Interactions**).

Enalapril maleate is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer enalapril maleate within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see **WARNINGS, Head and Neck Angioedema**).

WARNINGS

Anaphylactoid and Possibly Related Reactions

Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including enalapril maleate) may be subject to a variety of adverse reactions, some of them serious.

Head and Neck Angioedema

Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including enalapril maleate. This may occur at any time during treatment. In such cases enalapril maleate should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. **Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided (see ADVERSE REACTIONS**).

Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of

rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema (see **PRECAUTIONS**).

Intestinal Angioedema: Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.

Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see **INDICATIONS AND USAGE** and **CONTRAINDICATIONS**).

Anaphylactoid Reactions during Desensitization

Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.

Anaphylactoid Reactions during Membrane Exposure

Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patient undergoing low-density lipoprotein apheresis with dextran sulfate absorption.

Hypotension

Excessive hypotension is rare in uncomplicated hypertensive patients treated with enalapril maleate alone. Patients with heart failure given enalapril maleate commonly have some reduction in blood pressure, especially with the first dose, but discontinuation of therapy for continuing symptomatic hypotension usually is not necessary when dosing instructions are followed; caution should be observed when initiating therapy (see **DOSAGE AND ADMINISTRATION**). Patients at risk for excessive hypotension, sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high-dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. It may be advisable to eliminate the diuretic (except in patients with heart failure), reduce the diuretic dose or increase salt intake cautiously before initiating therapy with enalapril maleate in patients at risk for excessive hypotension who are able to tolerate such adjustments (see **PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS**). In patients at risk for excessive hypotension, therapy should be started under very close medical supervision and such patients should be followed closely for the first two weeks of treatment and whenever the dose of enalapril and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.

If excessive hypotension occurs, the patient should be placed in the supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive

response is not a contraindication to further doses of enalapril maleate, which usually can be given without difficulty once the blood pressure has stabilized. If symptomatic hypotension develops, a dose reduction or discontinuation of enalapril maleate or concomitant diuretic may be necessary.

Neutropenia/Agranulocytosis

Another angiotensin-converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment, especially if they also have a collagen vascular disease. Available data from clinical trials of enalapril are insufficient to show that enalapril does not cause agranulocytosis at similar rates. Marketing experience has revealed cases of neutropenia or agranulocytosis in which a causal relationship to enalapril cannot be excluded. Periodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered.

Hepatic Failure

Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis, and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.

Fetal Toxicity

Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue enalapril maleate tablets as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus.

In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intraamniotic environment. If oligohydramnios is observed, discontinue enalapril maleate tablets, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to enalapril maleate tablets for hypotension, oliguria, and hyperkalemia (see **PRECAUTIONS**, **Pediatric Use**).

No teratogenic effects of enalapril were seen in studies of pregnant rats and rabbits. On a body surface area basis, the doses used were 57 times and 12 times, respectively, the maximum recommended human daily dose (MRHDD).

PRECAUTIONS

General

Aortic Stenosis/Hypertrophic Cardiomyopathy

As with all vasodilators, enalapril should be given with caution to patients with obstruction in the outflow tract of the left ventricle.

Impaired Renal Function

As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin-converting enzyme inhibitors, including enalapril maleate, may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death (see **PRECAUTIONS, Drug Interactions**).

In clinical studies in hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine were observed in 20 percent of patients. These increases were almost always reversible upon discontinuation of enalapril and/or diuretic therapy. In such patients renal function should be monitored during the first few weeks of therapy.

Some patients with hypertension or heart failure with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when enalapril maleate has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or enalapril maleate may be required.

Evaluation of patients with hypertension or heart failure should always include assessment of renal function (see DOSAGE AND ADMINISTRATION).

Hyperkalemia

Elevated serum potassium (greater than 5.7 mEq/L) was observed in approximately one percent of hypertensive patients in clinical trials. In most cases these were isolated values which resolved despite continued therapy. Hyperkalemia was a cause of discontinuation of therapy in 0.28 percent of hypertensive patients. In clinical trials in heart failure, hyperkalemia was observed in 3.8 percent of patients but was not a cause for discontinuation.

Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with enalapril maleate (see **Drug Interactions**).

<u>Cough</u>

Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the differential diagnosis of cough.

Surgery/Anesthesia

In patients undergoing major surgery or during anesthesia with agents that produce hypotension, enalapril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.

Information for Patients

<u>Angioedema</u>

Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin- converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.

Hypotension

Patients should be cautioned to report lightheadedness, especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician. All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician.

<u>Hyperkalemia</u>

Patients should be told not to use salt substitutes containing potassium without consulting their physician.

<u>Neutropenia</u>

Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia.

<u>Pregnancy</u>

Female patients of childbearing age should be told about the consequences of exposure to enalapril maleate tablets during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.

NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

Drug Interactions

Neprilysin Inhibitors

Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema (see **WARNINGS**).

Dual Blockade of the Renin-Angiotensin System (RAS)

Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal

function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function, and electrolytes in patients on enalapril maleate tablets and other agents that affect the RAS.

Do not coadminister aliskiren with enalapril maleate in patients with diabetes. Avoid use of aliskiren with enalapril maleate in patients with renal impairment (GFR <60 mL/min).

<u>Hypotension — Patients on Diuretic Therapy</u>

Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril. The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril. If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour (see **WARNINGS, Hypotension** and **DOSAGE AND ADMINISTRATION**).

Agents Causing Renin Release

The antihypertensive effect of enalapril maleate is augmented by antihypertensive agents that cause renin release (e.g., diuretics).

<u>Nonsteroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors</u> (COX-2 Inhibitors)

In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including enalapril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving enalapril and NSAID therapy.

In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate. However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.

Other Cardiovascular Agents

Enalapril maleate has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.

Agents Increasing Serum Potassium

Enalapril maleate attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. Potassium-sparing agents should generally not be used in patients with heart failure receiving enalapril maleate.

<u>Lithium</u>

Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving concomitant enalapril maleate and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.

<u>Gold</u>

Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including enalapril maleate.

mTOR (Mammalian Target of Rapamycin) Inhibitors

Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see **WARNINGS, Head and Neck Angioedema**).

Carcinogenesis, Mutagenesis, Impairment of Fertility

There was no evidence of a tumorigenic effect when enalapril was administered for 106 weeks to male and female rats at doses up to 90 mg/kg/day or for 94 weeks to male and female mice at doses up to 90 and 180 mg/kg/day, respectively. These doses are 26 times (in rats and female mice) and 13 times (in male mice) the maximum recommended human daily dose (MRHDD) when compared on a body surface area basis.

Neither enalapril maleate nor the active diacid was mutagenic in the Ames microbial mutagen test with or without metabolic activation. Enalapril was also negative in the following genotoxicity studies: rec-assay, reverse mutation assay with *E. coli*, sister chromatid exchange with cultured mammalian cells, and the micronucleus test with mice, as well as in an *in vivo* cytogenic study using mouse bone marrow.

There were no adverse effects on reproductive performance of male and female rats treated with up to 90 mg/kg/day of enalapril (26 times the MRHDD when compared on a body surface area basis).

Pregnancy

Nursing Mothers

Enalapril and enalaprilat have been detected in human breast milk. Because of the potential for serious adverse reactions in nursing infants from enalapril, a decision should be made whether to discontinue nursing or to discontinue enalapril maleate, taking into account the importance of the drug to the mother.

Pediatric Use

Neonates with a History of In Utero Exposure to enalapril maleate

If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. Enalapril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion, although there is no experience with the latter procedure.

Antihypertensive effects of enalapril maleate have been established in hypertensive pediatric patients age 1 month to 16 years. Use of enalapril maleate in these age groups is supported by evidence from adequate and well-controlled studies of enalapril maleate in pediatric and adult patients as well as by published literature in pediatric patients (see **CLINICAL PHARMACOLOGY, Clinical Pharmacology in Pediatric Patients** and **DOSAGE AND ADMINISTRATION**).

Enalapril maleate is not recommended in neonates and in pediatric patients with glomerular filtration rate <30 mL/min/1.73 m2, as no data are available.

ADVERSE REACTIONS

Enalapril maleate has been evaluated for safety in more than 10,000 patients, including over 1000 patients treated for one year or more. Enalapril maleate has been found to be generally well tolerated in controlled clinical trials involving 2987 patients. For the most part, adverse experiences were mild and transient in nature. In clinical trials, discontinuation of therapy due to clinical adverse experiences was required in 3.3 percent of patients with hypertension and in 5.7 percent of patients with heart failure. The frequency of adverse experiences was not related to total daily dosage within the usual dosage ranges. In patients with hypertension the overall percentage of patients treated with enalapril maleate reporting adverse experiences was comparable to placebo.

Hypertension

Adverse experiences occurring in greater than one percent of patients with hypertension treated with enalapril maleate in controlled clinical trials are shown below. In patients treated with enalapril maleate, the maximum duration of therapy was three years; in placebo-treated patients the maximum duration of therapy was 12 weeks.

	Enalapril Maleate (n=2314) Incidence (discontinuation)	Placebo (n=230) Incidence
Body As A Whole		
Fatigue	3.0 (<0.1)	2.6
Orthostatic Effects	1.2 (<0.1)	0.0
Asthenia	1.1 (0.1)	0.9
Digestive		
Diarrhea	1.4 (<0.1)	1.7
Nausea	1.4 (0.2)	1.7
Nervous/Psychiatric		
Headache	5.2 (0.3)	9.1
Dizziness	4.3 (0.4)	4.3
Respiratory		

Cough	1.3 (0.1)	0.9
Skin		
Rash	1.4 (0.4)	0.4

Heart Failure

Adverse experiences occurring in greater than one percent of patients with heart failure treated with enalapril maleate are shown below. The incidences represent the experiences from both controlled and uncontrolled clinical trials (maximum duration of therapy was approximately one year). In the placebo- treated patients, the incidences reported are from the controlled trials (maximum duration of therapy is 12 weeks). The percentage of patients with severe heart failure (NYHA Class IV) was 29 percent and 43 percent for patients treated with enalapril maleate and placebo, respectively.

	Enalogril maleate (n=673) Incidence (discontinuation)	Placebo (n=339) Incidence
Body As A Whole		
Orthostatic Effects	2.2 (0.1)	0.3
Syncope	2.2 (0.1)	0.9
Chest Pain	2.1 (0.0)	2.1
Fatigue	1.8 (0.0)	1.8
Abdominal Pain	1.6 (0.4)	2.1
Asthenia	1.6 (0.1)	0.3
Cardiovascular		
Hypotension	6.7 (1.9)	0.6
Orthostatic Hypotension	1.6 (0.1)	0.3
Angina Pectoris	1.5 (0.1)	1.8
Myocardial Infarction	1.2 (0.3)	1.8
Digestive		
Diarrhea	2.1 (0.1)	1.2
Nausea	1.3 (0.1)	0.6
Vomiting	1.3 (0.0)	0.9
Nervous/Psychiatric	47. Cr.	
Dizziness	7.9 (0.6)	0.6
Headache	1.8 (0.1)	0.9
Vertigo	1.6 (0.1)	1.2
Respiratory		
Cough	2.2 (0.0)	0.6
Bronchitis	1.3 (0.0)	0.9
Dyspnea	1.3 (0.1)	0.4
Pneumonia	1.0 (0.0)	2.4
Skin		
Rash	1.3 (0.0)	2.4
Urogenital		
Urinary Tract Infection	1.3 (0.0)	2.4

Other serious clinical adverse experiences occurring since the drug was marketed or adverse experiences occurring in 0.5 to 1.0 percent of patients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing severity.

Body As A Whole: Anaphylactoid reactions (see **WARNINGS, Anaphylactoid and Possibly Related Reactions**).

Cardiovascular: Cardiac arrest; myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see **WARNINGS**, **Hypotension**); pulmonary embolism and infarction; pulmonary edema; rhythm

disturbances including atrial tachycardia and bradycardia; atrial fibrillation; palpitation, Raynaud's phenomenon.

Digestive: Ileus, pancreatitis, hepatic failure, hepatitis (hepatocellular [proven on rechallenge] or cholestatic jaundice) (see **WARNINGS, Hepatic Failure**), melena, anorexia, dyspepsia, constipation, glossitis, stomatitis, dry mouth.

Hematologic: Rare cases of neutropenia, thrombocytopenia and bone marrow depression.

Musculoskeletal: Muscle cramps.

Nervous/Psychiatric: Depression, confusion, ataxia, somnolence, insomnia, nervousness, peripheral neuropathy (e.g., paresthesia, dysesthesia), dream abnormality.

Respiratory: Bronchospasm, rhinorrhea, sore throat and hoarseness, asthma, upper respiratory infection, pulmonary infiltrates, eosinophilic pneumonitis.

Skin: Exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pemphigus, herpes zoster, erythema multiforme, urticaria, pruritus, alopecia, flushing, diaphoresis, photosensitivity.

Special Senses: Blurred vision, taste alteration, anosmia, tinnitus, conjunctivitis, dry eyes, tearing.

Urogenital: Renal failure, oliguria, renal dysfunction (see **PRECAUTIONS** and **DOSAGE AND ADMINISTRATION**), flank pain, gynecomastia, impotence.

Miscellaneous: A symptom complex has been reported which may include some or all of the following: a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia/myositis, fever, serositis, vasculitis, leukocytosis, eosinophilia, photosensitivity, rash and other dermatologic manifestations.

Angioedema: Angioedema has been reported in patients receiving enalapril maleate, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalapril maleate should be discontinued and appropriate therapy instituted immediately (see **WARNINGS, Head and Neck Angioedema**).

Hypotension: In the hypertensive patients, hypotension occurred in 0.9 percent and syncope occurred in 0.5 percent of patients following the initial dose or during extended therapy. Hypotension or syncope was a cause for discontinuation of therapy in 0.1 percent of hypertensive patients. In heart failure patients, hypotension occurred in 6.7 percent and syncope occurred in 2.2 percent of patients. Hypotension or syncope was a cause for discontinuation of syncope was a cause for discontinuation of therapy in 6.7 percent and syncope occurred in 2.2 percent of patients. Hypotension or syncope was a cause for discontinuation of therapy in 1.9 percent of patients with heart failure (see **WARNINGS, Hypotension**).

Cough: See **PRECAUTIONS, Cough**.

Pediatric Patients

The adverse experience profile for pediatric patients appears to be similar to that seen in adult patients.

Clinical Laboratory Test Findings

Serum Electrolytes

Hyperkalemia (see **PRECAUTIONS, Hyperkalemia**), hyponatremia.

Creatinine, Blood Urea Nitrogen

In controlled clinical trials minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 0.2 percent of patients with essential hypertension treated with enalapril maleate alone. Increases are more likely to occur in patients receiving concomitant diuretics or in patients with renal artery stenosis (see **PRECAUTIONS, Impaired Renal Function**). In patients with heart failure who were also receiving diuretics with or without digitalis, increases in blood urea nitrogen or serum creatinine, usually reversible upon discontinuation of enalapril maleate and/or other concomitant diuretic therapy, were observed in about 11 percent of patients. Increases in blood urea nitrogen or creatinine were a cause for discontinuation in 1.2 percent of patients.

<u>Hematology</u>

Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.3 g percent and 1.0 vol percent, respectively) occur frequently in either hypertension or congestive heart failure patients treated with enalapril maleate but are rarely of clinical importance unless another cause of anemia coexists. In clinical trials, less than 0.1 percent of patients discontinued therapy due to anemia. Hemolytic anemia, including cases of hemolysis in patients with G6PD deficiency, has been reported; a causal relationship to enalapril cannot be excluded.

Liver Function Tests

Elevations of liver enzymes and/or serum bilirubin have occurred (see **WARNINGS**, **Hepatic Failure**).

To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

Limited data are available in regard to overdosage in humans.

Single oral doses of enalapril above 1,000 mg/kg and \geq 1,775 mg/kg were associated with lethality in mice and rats, respectively.

The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution.

Enalaprilat may be removed from general circulation by hemodialysis and has been removed from neonatal circulation by peritoneal dialysis (see **WARNINGS**, **Anaphylactoid Reactions during Membrane Exposure**).

DOSAGE AND ADMINISTRATION

Hypertension

In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of enalapril maleate tablets. The diuretic should, if possible, be discontinued for two to three days before beginning therapy with enalapril maleate tablets to reduce the likelihood of hypotension (see **WARNINGS**, **Hypotension**). If the patient's blood pressure is not controlled with enalapril maleate tablets alone, diuretic therapy may be resumed.

If the diuretic cannot be discontinued an initial dose of 2.5 mg should be used under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see **WARNINGS, Hypotension** and **PRECAUTIONS, Drug Interactions**).

The recommended initial dose in patients not on diuretics is 5 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 10 to 40 mg per day administered in a single dose or two divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. In such patients, an increase in dosage or twice daily administration should be considered. If blood pressure is not controlled with enalapril maleate tablets alone, a diuretic may be added. Concomitant administration of enalapril maleate tablets with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics may lead to increases of serum potassium (see **PRECAUTIONS**).

Dosage Adjustment in Hypertensive Patients with Renal Impairment

The usual dose of enalapril is recommended for patients with a creatinine clearance more than 30 mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance less than or equal to 30 mL/min (serum creatinine more than or equal to 3 mg/dL), the first dose is 2.5 mg once daily. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily.

Renal Status	Creatinine Clearance mL/min	Initial Dose mg/day
Normal Renal Function	>80 mL/min	5 mg
Mild Impairment	≤ 80 >30 mL/min	5 mg
Moderate to Severe Impairment	≤30 mL/min	2.5 mg
Dialysis Patients ¹		2.5 mg on dialysis days ²
¹ See WARNINGS, Anaphylactoid R Exposure.	eactions during Membrane	
² Dosage on nondialysis days should	d be adjusted depending on the bloo	d pressure response.

Enalapril maleate tablets are indicated for the treatment of symptomatic heart failure, usually in combination with diuretics and digitalis. In the placebo-controlled studies that demonstrated improved survival, patients were titrated as tolerated up to 40 mg, administered in two divided doses.

The recommended initial dose is 2.5 mg. The recommended dosing range is 2.5 to 20 mg given twice a day. Doses should be titrated upward, as tolerated, over a period of a few days or weeks. The maximum daily dose administered in clinical trials was 40 mg in divided doses.

After the initial dose of enalapril maleate tablets, the patient should be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see **WARNINGS** and **PRECAUTIONS, Drug Interactions**). If possible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of hypotension. The appearance of hypotension after the initial dose of enalapril maleate tablets does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension.

Asymptomatic Left Ventricular Dysfunction

In the trial that demonstrated efficacy, patients were started on 2.5 mg twice daily and were titrated as tolerated to the targeted daily dose of 20 mg (in divided doses).

After the initial dose of enalapril maleate tablets, the patient should be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see **WARNINGS** and **PRECAUTIONS, Drug Interactions**). If possible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of hypotension. The appearance of hypotension after the initial dose of enalapril maleate tablets does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension.

Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hyponatremia

In patients with heart failure who have hyponatremia (serum sodium less than 130 mEq/L) or with serum creatinine greater than 1.6 mg/dL, therapy should be initiated at 2.5 mg daily under close medical supervision (see **DOSAGE AND ADMINISTRATION**, **Heart Failure, WARNINGS** and **PRECAUTIONS**, **Drug Interactions**). The dose may be increased to 2.5 mg b.i.d., then 5 mg b.i.d. and higher as needed, usually at intervals of four days or more if at the time of dosage adjustment there is not excessive hypotension or significant deterioration of renal function. The maximum daily dose is 40 mg.

Pediatric Hypertensive Patients

The usual recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily. Dosage should be adjusted according to blood pressure response. Doses above 0.58 mg/kg (or in excess of 40 mg) have not been studied in pediatric patients (see **CLINICAL PHARMACOLOGY, Clinical Pharmacology in Pediatric Patients**).

Enalapril maleate is not recommended in neonates and in pediatric patients with glomerular filtration rate less than 30 mL/min/1.73 m2, as no data are available.

Preparation of Suspension (for 200 mL of a 1.0 mg/mL suspension)

Add 50 mL of sodium citrate and citric acid oral solution, USP to a polyethylene terephthalate (PET) bottle containing ten 20 mg tablets of enalapril maleate tablets and shake for at least 2 minutes. Let concentrate stand for 60 minutes. Following the 60minute hold time, shake the concentrate for an additional minute. Add 150 mL of Ora-Sweet SF to the concentrate in the PET bottle and shake the suspension to disperse the ingredients. The suspension should be refrigerated at 2° to 8°C (36° to 46°F) and can be stored for up to 30 days. Shake the suspension before each use.

HOW SUPPLIED

Enalapril maleate tablets USP, 2.5 mg are available as yellow, oval, convex tablets debossed "704" on one side and bisect on the other side.

They are supplied as follows:

NDC 23155-704-01 bottles of 100 (with desiccant)

NDC 23155-704-10 bottles of 1000 (with desiccant)

Enalapril maleate tablets USP, 5 mg are available as white, oval, convex tablets debossed "705" on one side and bisect on the other side.

They are supplied as follows:

NDC 23155-705-01 bottles of 100 (with desiccant)

NDC 23155-705-10 bottles of 1000 (with desiccant)

Enalapril maleate tablets USP, 10 mg are available as salmon, oval, convex tablets debossed "706" on one side and bisect on the other side.

They are supplied as follows:

NDC 23155-772-01 bottles of 100 (with desiccant)

NDC 23155-772-10 bottles of 1000 (with desiccant)

Enalapril maleate tablets USP, 20 mg are available as peach, oval, convex tablets debossed "707" on one side and bisect on the other side.

They are supplied as follows:

NDC 23155-773-01	bottles of 100 (with desiccant)
NDC 23155-773-05	bottles of 500 (with desiccant)
NDC 23155-773-10	bottles of 1000 (with desiccant)

Storage

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Keep container tightly closed. Protect from moisture.

Dispense in a tight container as per USP, if product package is subdivided.

All brand names listed are the registered trademarks of their respective owners and are

not the trademarks of Avet Pharmaceuticals. Distributed by:

Avet Pharmaceuticals Inc.

East Brunswick, NJ 08816 1.866.901.DRUG (3784)



51U000000368US02

Revised: 11/2023

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 23155-704-01

Enalapril Maleate Tablets USP

2.5 mg

100 Tablets

Rx only



NDC 23155-705-01

Enalapril Maleate Tablets USP

5 mg

100 Tablets

Rx only



NDC 23155-706-01

Enalapril Maleate Tablets USP

10 mg

100 Tablets

Rx only



NDC 23155-707-01

Enalapril Maleate Tablets USP

20 mg

100 Tablets

Rx only



NDC 23155-772-01

Enalapril Maleate Tablets USP

10 mg

100 Tablets

Rx only



NDC 23155-773-01

Enalapril Maleate Tablets USP

20 mg

100 Tablets

Rx only

NDC 23155-773-01 Enalapril Maleate Tablets USP 20 mg	P. ge: See package insert for full information. to 25°C (68° to 77°F) [See lled Room Temperature]. ner tightly closed. n moisture. ins desiccant. a tight, light-resistant defined in the USP, with a int closure (as required). AND ALL MEDICATIONS OUT CH OF CHILDREN. DY: acenticals Inc.	5 5 - 7 7 3 - 0 1 9
100 Tablets Rx only	US 005 005 005 005 005 005 005 00	Non Non
🛟 Avet Pharma®	Maleate, Usual D prescrib Store at USP Cou USP Cou Protect i Bottle o Dispens containe child-res KEEP THE Distribut	5110000 5110000 3

ENALAPRIL MALE	ATE					
enalapril maleate tablet						
Product Information						
Product Type	HUMAN PRE	SCRIPTION DRUG	ltem Code	(Source)	NDC:2	3155-704
Route of Administration	ORAL					
Active Ingredient/Act	tive Moiety					
	Ingredient N	ame		Basis o Streng		Strength
ENALAPRIL MALEATE (UNII: 9 UNII:Q508Q118JM)	9025354EPJ) (ENA	LAPRILAT ANHYDROUS	-	ENALAPRIL MA	LEATE	2.5 mg
01111 (000 (220), 1)						
Inactive Ingredients						
	Ingred	ient Name			St	rength
LACTOSE MONOHYDRATE (-					
STARCH, CORN (UNII: 08232	INY 35J)					
STARCH, CORN (UNII: 08232 SODIUM BICARBONATE (UN	-					
	III: 8MDF5V39QO)					
SODIUM BICARBONATE (UN	III: 8MDF5V39QO)					
SODIUM BICARBONATE (UN MAGNESIUM STEARATE (UN	III: 8MDF5V39QO) III: 70097M6I30)					
SODIUM BICARBONATE (UN MAGNESIUM STEARATE (UN WATER (UNII: 059QF0K00R)	HII: 8MDF5V39QO) HII: 70097M6I30) H77VEI93A8)	64F7XSTX)				
SODIUM BICARBONATE (UN MAGNESIUM STEARATE (UN WATER (UNII: 059QF0K00R) FD&C YELLOW NO. 6 (UNII:	III: 8MDF5V39QO) III: 70097M6I30) H77VEI93A8) M LAKE (UNII: ZK					
SODIUM BICARBONATE (UN MAGNESIUM STEARATE (UN WATER (UNII: 059QF0KO0R) FD&C YELLOW NO. 6 (UNII: D&C RED NO. 27 ALUMINUI	III: 8MDF5V39QO) III: 70097M6I30) H77VEI93A8) M LAKE (UNII: ZKG IINUM LAKE (UNI	I: CQ3XH3DET6)				
SODIUM BICARBONATE (UN MAGNESIUM STEARATE (UN WATER (UNII: 059QF0KO0R) FD&C YELLOW NO. 6 (UNII: D&C RED NO. 27 ALUMINUM D&C YELLOW NO. 10 ALUM	III: 8MDF5V39QO) III: 70097M6I30) H77VEI93A8) M LAKE (UNII: ZKI IINUM LAKE (UNII JM LAKE (UNII: J9	I: CQ3XH3DET6)				
SODIUM BICARBONATE (UN MAGNESIUM STEARATE (UN WATER (UNII: 059QF0KO0R) FD&C YELLOW NO. 6 (UNII: D&C RED NO. 27 ALUMINU D&C YELLOW NO. 10 ALUM FD&C BLUE NO. 1 ALUMINU	III: 8MDF5V39QO) III: 70097M6I30) H77VEI93A8) M LAKE (UNII: ZKI IINUM LAKE (UNII JM LAKE (UNII: J9	I: CQ3XH3DET6)				
SODIUM BICARBONATE (UN MAGNESIUM STEARATE (UN WATER (UNII: 059QF0KO0R) FD&C YELLOW NO. 6 (UNII: D&C RED NO. 27 ALUMINU D&C YELLOW NO. 10 ALUM FD&C BLUE NO. 1 ALUMINU	III: 8MDF5V39QO) III: 70097M6I30) H77VEI93A8) M LAKE (UNII: ZKO IINUM LAKE (UNII: J9 B9127XOA)	I: CQ3XH3DET6)				
SODIUM BICARBONATE (UN MAGNESIUM STEARATE (UN WATER (UNII: 059QF0KO0R) FD&C YELLOW NO. 6 (UNII: D&C RED NO. 27 ALUMINU D&C YELLOW NO. 10 ALUM FD&C BLUE NO. 1 ALUMINU FD&C RED NO. 40 (UNII: WZ Product Characterist	III: 8MDF5V39QO) III: 70097M6I30) H77VEI93A8) M LAKE (UNII: ZKO IINUM LAKE (UNII: J9 B9127XOA)	I: CQ3XH3DET6)			2 pieces	5
SODIUM BICARBONATE (UN MAGNESIUM STEARATE (UN WATER (UNII: 059QF0KO0R) FD&C YELLOW NO. 6 (UNII: D&C RED NO. 27 ALUMINU D&C YELLOW NO. 10 ALUM FD&C BLUE NO. 1 ALUMINU FD&C RED NO. 40 (UNII: WZ Product Characterist Color YE	III: 8MDF5V39QO) III: 70097M6I30) H77VEI93A8) M LAKE (UNII: ZKI IINUM LAKE (UNII: J9 B9127XOA)	I: CQ3XH3DET6) EQA3S2JM)			2 pieces 9mm	5
SODIUM BICARBONATE (UN MAGNESIUM STEARATE (UN WATER (UNII: 059QF0KO0R) FD&C YELLOW NO. 6 (UNII: D&C RED NO. 27 ALUMINU D&C YELLOW NO. 10 ALUM FD&C BLUE NO. 1 ALUMINU FD&C RED NO. 40 (UNII: WZ Product Characterist Color YE	III: 8MDF5V39QO) III: 70097M6I30) H77VEI93A8) M LAKE (UNII: ZKO IINUM LAKE (UNII: ZKO IINUM LAKE (UNII: J9 B9127XOA) CICS	I: CQ3XH3DET6) EQA3S2JM) Score	Code	!		5

	ackaging								
#	ltem Code	Pa	ckage Description		Marketing Date			ing End ate	
1		100 in 1 BOTT Product	LE; Type 0: Not a Combinatio	n 0	4/28/2020				
2		1000 in 1 BOT Product	TLE; Type 0: Not a Combinati	on 0	4/28/2020				
M	larketing I	nformat	ion						
	Marketing Category	Applica	tion Number or Monogra Citation	aph	Marketin Dat			ting End ate	
AN	DA	ANDA07547	9		04/28/2020				
Eľ	VALAPRIL	MALEAT	E						
en	alapril maleate	tablet							
	· ·								
Ρ	roduct Inform	mation							
Pı	roduct Type		HUMAN PRESCRIPTION DRUG	i	ltem Code ((Source)	NDC:2	3155-705	
R	oute of Adminis	stration	ORAL						
A	ctive Ingredie	ent/Active	Moiety						
		Active Ingredient/Active Moiety Basis of Ctrought							
		Ind	radiant Nama			Bas	is of	Strongtl	
		Ing	redient Name				is of ngth	Strengtl	
		-	redient Name 354EPJ) (ENALAPRILAT ANHYDI	ROUS -			ngth	Strengti 5 mg	
	IALAPRIL MALEA III:Q508Q118JM)	-		ROUS -		Stre	ngth		
		-		ROUS -		Stre	ngth		
UN	III:Q508Q118JM)	TE (UNII: 9025		ROUS -		Stre	ngth		
UN		TE (UNII: 9025	354EPJ) (ENALAPRILAT ANHYDI	ROUS -		Stre	ngth MALEATE	5 mg	
In	III:Q508Q118JM) active Ingree	TE (UNII: 9025	354EPJ) (ENALAPRILAT ANHYDI Ingredient Name	ROUS -		Stre	ngth MALEATE		
	III:Q508Q118JM) active Ingree CTOSE MONOHY	TE (UNII: 9025 dients (DRATE (UNII:	354EPJ) (ENALAPRILAT ANHYDI Ingredient Name EWQ57Q8I5X)	ROUS -		Stre	ngth MALEATE	5 mg	
UN In LA	III:Q508Q118JM) active Ingree	TE (UNII: 9025 dients (DRATE (UNII: III: 08232NY35	354EPJ) (ENALAPRILAT ANHYDI Ingredient Name EWQ57Q8I5X) J)	ROUS -		Stre	ngth MALEATE	5 mg	
In LA ST	III:Q508Q118JM) active Ingree CTOSE MONOHY ARCH, CORN (UN	TE (UNII: 9025 dients (DRATE (UNII: III: 08232NY35 NATE (UNII: 8M	354EPJ) (ENALAPRILAT ANHYDI Ingredient Name EWQ57Q8I5X) J) IDF5V39QO)	ROUS -		Stre	ngth MALEATE	5 mg	
UN LA ST SC M/	III:Q508Q118JM) active Ingred CTOSE MONOHY ARCH, CORN (UN DOIUM BICARBOI	TE (UNII: 9025 dients (DRATE (UNII: III: 08232NY3S NATE (UNII: 8M RATE (UNII: 70	354EPJ) (ENALAPRILAT ANHYDI Ingredient Name EWQ57Q8I5X) J) IDF5V39QO)	ROUS -		Stre	ngth MALEATE	5 mg	
UN LA ST SC M/	AGNESIUM STEAL	TE (UNII: 9025 dients (DRATE (UNII: III: 08232NY3S NATE (UNII: 8M RATE (UNII: 70	354EPJ) (ENALAPRILAT ANHYDI Ingredient Name EWQ57Q8I5X) J) IDF5V39QO)	ROUS -		Stre	ngth MALEATE	5 mg	
LA ST SC M/	AGNESIUM STEAL	TE (UNII: 9025 dients /DRATE (UNII: III: 08232NY3S NATE (UNII: 8M RATE (UNII: 70 FOKOOR)	354EPJ) (ENALAPRILAT ANHYDI Ingredient Name EWQ57Q8I5X) J) IDF5V39QO)	ROUS -		Stre	ngth MALEATE	5 mg	
In LA ST M/ W	III:Q508Q118JM) ACTOSE MONOHY ARCH, CORN (UN DOIUM BICARBOI AGNESIUM STEAL ATER (UNII: 059Q)	TE (UNII: 9025 dients /DRATE (UNII: III: 08232NY3S NATE (UNII: 8M RATE (UNII: 70 FOKOOR)	354EPJ) (ENALAPRILAT ANHYDI Ingredient Name EWQ57Q8I5X) J) IDF5V39QO) 097M6I30)	ROUS -		Stre	ngth MALEATE	5 mg	
In LA ST SC M/ W	III:Q508Q118JM) active Ingree CTOSE MONOHY ARCH, CORN (UN DIUM BICARBOI AGNESIUM STEAL ATER (UNII: 059QI ATER (UNII: 059QI	TE (UNII: 9025 dients (DRATE (UNII: III: 08232NY3S NATE (UNII: 8M RATE (UNII: 70 F0K00R) (cteristics	354EPJ) (ENALAPRILAT ANHYDI Ingredient Name EWQ57Q8I5X) J) IDF5V39QO) 097M6I30) Sc	ore		Stre	ngth MALEATE Stre	5 mg	
In LA ST SC M/ W/ PI Cc Sh	III:Q508Q118JM) active Ingred CTOSE MONOHY ARCH, CORN (UN DOIUM BICARBOI AGNESIUM STEAI ATER (UNII: 059QI ATER (UNII: 059QI roduct Chara	TE (UNII: 9025 dients (DRATE (UNII: III: 08232NY3S NATE (UNII: 8M RATE (UNII: 70 F0KO0R) (cteristics WHITE	354EPJ) (ENALAPRILAT ANHYD Ingredient Name EWQ57Q8I5X) J) DF5V39QO) 097M6I30) Sc Sc Siz	ore	Code	Stre	ng th MALEATE Stre	5 mg	

Pa	ackaging						
#	ltem Code	Pa	ckage Description	Marketing Date			ing End ate
1	NDC:23155-705- 01	100 in 1 BOTT Product	LE; Type 0: Not a Combination	04/28/2020			
2	NDC:23155-705- 10	1000 in 1 BOT Product	TLE; Type 0: Not a Combination	04/28/2020			
M	larketing	Informat	ion				
	Marketing Category	Applica	tion Number or Monograph Citation	Marketin Dat	-		ting End ate
			<u>.</u>	04/28/2020			
		ANDA07547		04/20/2020			
Eľ		MALEATI		04/20/2020			
Eľ en	NALAPRIL	MALEATI tablet		04/20/2020			
E I en Pi	NALAPRIL alapril maleate	MALEATI tablet		ltem Code (Source)	NDC:2	3155-706
Eľ en Pi	NALAPRIL alapril maleate roduct Infor	MALEATI tablet mation	- E		Source)	NDC:2	3155-706
Eľ en Pi	NALAPRIL alapril maleate roduct Infor roduct Type	MALEATI tablet mation	E HUMAN PRESCRIPTION DRUG		Source)	NDC:2	3155-706
EN en Pi Ro	NALAPRIL alapril maleate roduct Infor roduct Type	MALEATI tablet mation	HUMAN PRESCRIPTION DRUG ORAL		Source)	NDC:2	3155-706
EN en Pi Ro	NALAPRIL alapril maleate roduct Infor roduct Type pute of Admini	MALEATI tablet mation stration	HUMAN PRESCRIPTION DRUG ORAL		Source) Basi Strer	s of	3155-706 Strengtl

Inactive Ingredients					
Ingredient Name	Strength				
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)					
STARCH, CORN (UNII: 08232NY3SJ)					
SODIUM BICARBONATE (UNII: 8MDF5V39QO)					
FD&C RED NO. 40 (UNII: WZ B9127XOA)					
FD&C BLUE NO. 2 (UNII: L06K8R7DQK)					
FD&C YELLOW NO. 6 (UNII: H77VEI93A8)					
WATER (UNII: 059QF0KO0R)					
MAGNESIUM STEARATE (UNII: 70097M6I30)					

Product Characteristics							
Color	PINK (salmon)	Score	no score				
Shape	OVAL (convex)	Size	10mm				
Flavor		Imprint Code	706				
Contains							

	ackaging							
#	ltem Code	Pa	ckage Description		Marketing Date			ing End ate
	NDC:23155-706- 01	100 in 1 BOTT Product	LE; Type 0: Not a Combina	ation	04/28/2020		04/29/2020)
	NDC:23155-706- 10	1000 in 1 BOT Product	TLE; Type 0: Not a Combir	nation	04/28/2020		04/29/2020	
Μ	arketing	Informat	ion					
	Marketing Category	Applica	tion Number or Mono Citation	graph	Marketin Dat			ting End ate
AN	DA	ANDA07547	9		04/28/2020		04/29/202	0
			_					
			=					
ana	alapril maleate	tablet						
Pr	roduct Infor	mation						
Pr	oduct Type		HUMAN PRESCRIPTION DE	RUG	Item Code (Source)	NDC:2	3155-707
Ro	ute of Admini	stration	ORAL					
Ac	tive Ingredi	ent/Active	Moiety					
		Ing	redient Name				sis of ength	Strengt
	ALAPRIL MALEA II:Q508Q118JM)	TE (UNII: 9025	354EPJ) (ENALAPRILAT ANH	IYDROUS	-		_ MALEATE	20 mg
	active Ingre	dients						
Ina			Ingredient Name				Stre	ength
			•					
LAC	стоѕе молон							
LAC ST/	ARCH, CORN (U	NII: 08232NY3S])					
LA(ST/ SO	ARCH, CORN (U DIUM BICARBO	NII: 08232NY3S NATE (UNII: 8M	J) DF5V39QO)					
LA(ST/ SO FD	ARCH, CORN (U DIUM BICARBO &C YELLOW NO	NII: 08232NY3S NATE (UNII: 8M). 6 (UNII: H77V	J) DF5V39QO)					
LAC ST/ SO FD	ARCH, CORN (U DIUM BICARBO &C YELLOW NO ATER (UNII: 059Q	NII: 08232NY3S NATE (UNII: 8M D. 6 (UNII: H77V FOKOOR)	J) DF5V39QO) EI93A8)					
LA(ST/ SO FD	ARCH, CORN (U DIUM BICARBO &C YELLOW NO	NII: 08232NY3S NATE (UNII: 8M D. 6 (UNII: H77V FOKOOR)	J) DF5V39QO) EI93A8)					
LAC ST/ SO FD WA MA	ARCH, CORN (U DIUM BICARBO &C YELLOW NO ATER (UNII: 059Q	NII: 08232NY3S NATE (UNII: 8M). 6 (UNII: H77V PFOKOOR) RATE (UNII: 70	J) DF5V39QO) EI93A8)					
LAC ST SO FD WA MA	ARCH, CORN (U DIUM BICARBO &C YELLOW NO ATER (UNII: 059Q AGNESIUM STEA	NII: 08232NY3S NATE (UNII: 8M). 6 (UNII: H77V PFOKOOR) RATE (UNII: 70	J) DF5V39QO) EI93A8) D97M6I30)	Score			no score	2
LAC ST/ SO FD WA MA Pr Co	ARCH, CORN (U DIUM BICARBO &C YELLOW NO ATER (UNII: 059Q GNESIUM STEA	NII: 08232NY3S NATE (UNII: 8M D. 6 (UNII: H77V FOKOOR) RATE (UNII: 70 ACTERISTICS	J) DF5V39QO) EI93A8) D97M6I30)	Score Size			no score 10mm	1
LAC ST/ SO FD WA MA Pr Co Sh	ARCH, CORN (U DIUM BICARBO &C YELLOW NO ATER (UNII: 059Q GONESIUM STEA Oduct Chara	NII: 08232NY3S NATE (UNII: 8M D. 6 (UNII: H77V FOKOOR) NRATE (UNII: 70 ACTERISTICS PINK (pe	J) DF5V39QO) EI93A8) D97M6I30) each) ponvex)		Code			2

	ackaging							
#	ltem Code	Pa	kage Description	Marketing Dat			ing End ate	
1	NDC:23155-707- 01	100 in 1 BOTT Product	LE; Type 0: Not a Combination	04/28/2020		04/29/2020		
2	NDC:23155-707- 05	500 in 1 BOTT Product	LE; Type 0: Not a Combination	04/28/2020		04/29/2020		
3	NDC:23155-707- 10	1000 in 1 BOT Product	TLE; Type 0: Not a Combination	04/28/2020		04/29/2020		
M	larketing	Informat	ion					
	Marketing Category	Applicat	tion Number or Monograp Citation	h Marketii Da			ting End ate	
AN	IDA	ANDA075479	9	04/28/2020		04/29/202	0	
	alapril maleate							
		mation	HUMAN PRESCRIPTION DRUG		(6	NDC-2	3155-772	
	roduct Type oute of Admini		ORAL	Item Code	(Source)	NDC:2	3133-772	
A	ctive Ingredi	ent/Active	Moiety					
A	ctive Ingredi		Moiety redient Name			is of ngth	Strengt	
E١		Ing	-	JS -	Stre			
E î Un	NALAPRIL MALEA	ing TE (UNII: 9025:	redient Name	JS -	Stre	ngth		
E I UN	VALAPRIL MALEA VIII:Q508Q118JM)	ing TE (UNII: 9025:	redient Name	JS -	Stre	ngth MALEATE		
EP UN Ir	ALAPRIL MALEA	Ing TE (UNII: 9025: dients YDRATE (UNII:	redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X)	JS -	Stre	ngth MALEATE	10 mg	
EN UN Ir	ALAPRIL MALEA MII:Q508Q118JM) ACTOSE MONOH FARCH, CORN (UI	Ing TE (UNII: 9025: dients YDRATE (UNII: NII: 08232NY35	redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X)	JS -	Stre	ngth MALEATE	10 mg	
EN UN Ir LA ST	ALAPRIL MALEA MII:Q508Q118JM) ACTOSE MONOH ACTOSE MONOH ARCH, CORN (UI	ing TE (UNII: 9025: dients YDRATE (UNII: NII: 08232NY35 NATE (UNII: 8M	redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X) J) DF5V39QO)	JS -	Stre	ngth MALEATE	10 mg	
EN UN Ir ST SC FC	ALAPRIL MALEA MII:Q508Q118JM) ACTOSE MONOH FARCH, CORN (UI DDIUM BICARBO D&C RED NO. 40	Ing TE (UNII: 9025: dients YDRATE (UNII: NII: 08232NY35 NATE (UNII: 8M (UNII: WZB912	redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X) J) DF5V39QO) 7XOA)	JS -	Stre	ngth MALEATE	10 mg	
EN UN Ir SI SC FC	ALAPRIL MALEA MII:Q508Q118JM) ACTOSE MONOH ACTOSE MONOH ARCH, CORN (UI	Ing TE (UNII: 9025: dients YDRATE (UNII: NII: 08232NY35 NATE (UNII: 8M (UNII: WZ B912' (UNII: L06K8R7	redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X) I) DF5V39QO) 7XOA) DQK)	JS -	Stre	ngth MALEATE	10 mg	
ENUN Ir SC FC FC	ALAPRIL MALEA MII:Q508Q118JM) ACTOSE MONOH ACTOSE MONOH ARCH, CORN (UI DDIUM BICARBO D&C RED NO. 40 D&C BLUE NO. 2	Ing TE (UNII: 9025: dients YDRATE (UNII: NII: 08232NY35, NATE (UNII: 8M (UNII: WZ B912 (UNII: L06K8R7). 6 (UNII: H77V	redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X) I) DF5V39QO) 7XOA) DQK)	JS -	Stre	ngth MALEATE	10 mg	
EP UN Ir ST SC FC FC	ALAPRIL MALEA MII:Q508Q118JM) ACTOSE MONOH TARCH, CORN (UI DDIUM BICARBO D&C RED NO. 40 D&C BLUE NO. 2 D&C YELLOW NO	Ing TE (UNII: 9025: dients YDRATE (UNII: NII: 08232NY35 NATE (UNII: 8M (UNII: 08232NY35) (UNII: 08232NY35) 0.6 (UNII: H77V F0KO0R)	redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X) J) DF5V39QO) 7XOA) DQK) EI93A8)	JS -	Stre	ngth MALEATE	10 mg	
EPUN Ir SC FC FC W	ALAPRIL MALEA MII:Q508Q118JM) ACTOSE MONOH ACTOSE MONOH ARCH, CORN (UI DDIUM BICARBO D&C RED NO. 40 D&C BLUE NO. 2 D&C YELLOW NO ATER (UNII: 059Q	Ing TE (UNII: 9025: dients YDRATE (UNII: NII: 08232NY35 NATE (UNII: 8M (UNII: WZ B912 ⁻¹ (UNII: WZ B912 ⁻¹ (UNII: WZ B912 ⁻¹ (UNII: WZ B912 ⁻¹ (UNII: UO6K8R7 D. 6 (UNII: H77V FOKOOR) RATE (UNII: 700	redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X) J) DF5V39QO) 7XOA) DQK) EI93A8)	JS -	Stre	ngth MALEATE	10 mg	
	ALAPRIL MALEA MII:Q508Q118JM) ACTOSE MONOH TARCH, CORN (UI DDIUM BICARBO D&C RED NO. 40 D&C BLUE NO. 2 D&C YELLOW NO ATER (UNII: 059Q AGNESIUM STEA	Ing TE (UNII: 9025: dients YDRATE (UNII: NII: 08232NY35 NATE (UNII: 8M (UNII: WZ B912 ⁻¹ (UNII: WZ B912 ⁻¹ (UNII: WZ B912 ⁻¹ (UNII: WZ B912 ⁻¹ (UNII: UO6K8R7 D. 6 (UNII: H77V FOKOOR) RATE (UNII: 700	redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X))) DF5V39QO) 7XOA) DQK) EI93A8) D97M6I30)		Stre	ngth MALEATE	ngth	
ENUN Ir SC FC FC W M	ALAPRIL MALEA MII:Q508Q118JM) ACTOSE MONOH ACTOSE MONOH ARCH, CORN (UI DDIUM BICARBO D&C RED NO. 40 D&C BLUE NO. 2 D&C YELLOW NO ATER (UNII: 059Q AGNESIUM STEA	Ing TE (UNII: 9025: dients YDRATE (UNII: NII: 08232NY35 NATE (UNII: 8M (UNII: 08232NY35) NATE (UNII: 8M (UNII: WZ B912 (UNII: WZ B912 (UNII: L06K8R7 0.6 (UNII: H77V F0KO0R) RATE (UNII: 700 RATE (UNII: 700	redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X))) DF5V39QO) 7XOA) DQK) EI93A8) D97M6I30) Score		Stre	MALEATE	10 mg	

	ontains						
Pa	ackaging						
#	ltem Code	Pa	ckage Description	Marketing Date	-		ing End ate
1	NDC:23155-772- 01	100 in 1 BOTT Product	LE; Type 0: Not a Combination	10/01/2020			
2	NDC:23155-772- 10	1000 in 1 BOT Product	TLE; Type 0: Not a Combination	10/01/2020			
Μ	larketing	Informat	ion				
	Marketing Category	Applica	tion Number or Monograph Citation	Marketiı Da	-		ting End ate
AN	DA	ANDA07547	9	10/01/2020			
ena	NALAPRIL alapril maleate	tablet	E				
en Pi	alapril maleate roduct Infor	tablet			· · · · · · · · · · · · · · · · · · ·		
en Pi Pr	alapril maleate roduct Infor roduct Type	tablet mation	HUMAN PRESCRIPTION DRUG	Item Code	(Source)	NDC:2	3155-773
en Pi Pr	alapril maleate roduct Infor	tablet mation		Item Code	(Source)	NDC:2	3155-773
Pr Pr Rc	alapril maleate roduct Infor roduct Type	tablet mation stration	HUMAN PRESCRIPTION DRUG ORAL	Item Code	(Source)	NDC:2	3155-773
en Pr Pr Ro	alapril maleate roduct Infor roduct Type pute of Admini	tablet mation stration ent/Active	HUMAN PRESCRIPTION DRUG ORAL	Item Code	Basi	NDC:2. is of ngth	3155-773 Streng
ena Pr Ro Ac	alapril maleate roduct Infor roduct Type oute of Admini	tablet mation stration ent/Active Ing	HUMAN PRESCRIPTION DRUG ORAL Moiety		Basi	is of ngth	
Pr Pr Rc Ac	alapril maleate roduct Infor roduct Type oute of Admini ctive Ingredi	tablet mation stration ent/Active Ing TE (UNII: 9025	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name		Basi	is of ngth	Streng
Pr Pr Rc Ac	alapril maleate roduct Infor roduct Type oute of Admini ctive Ingredi	tablet mation stration ent/Active Ing TE (UNII: 9025	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name		Basi	is of ngth MALEATE	Streng
eni Pr Rc Ac	alapril maleate roduct Infor roduct Type oute of Admini ctive Ingredi	tablet mation stration ent/Active Ing TE (UNII: 9025 dients	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name		Basi	is of ngth MALEATE	Streng 20 mg
Pr Ra Ac In	alapril maleate roduct Infor roduct Type oute of Admini ctive Ingredi IALAPRIL MALEA IIII:Q508Q118JM) active Ingre	tablet mation stration ent/Active Ing TE (UNII: 9025 dients yDRATE (UNII: NII: 08232NY35	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X) J)		Basi	is of ngth MALEATE	Streng 20 mg
eni Pr Ro Ac EN UN	alapril maleate roduct Infor roduct Type oute of Admini ctive Ingredi IALAPRIL MALEA III: Q508Q118JM)	tablet mation stration ent/Active ing TE (UNII: 9025 dients dients YDRATE (UNII: NII: 08232NY3S NATE (UNII: 8M	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X) J) IDF5V39QO)		Basi	is of ngth MALEATE	Streng 20 mg
ena Pr Ra Aa EN UN In LA ST SO FD	alapril maleate roduct Infor roduct Type oute of Admini ctive Ingredi IALAPRIL MALEA III:Q508Q118JM) active Ingre CTOSE MONOH ARCH, CORN (UI	tablet mation stration ent/Active ing TE (UNII: 9025 dients dients YDRATE (UNII: NII: 08232NY3S NATE (UNII: 8M 0. 6 (UNII: H77V	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name 354EPJ) (ENALAPRILAT ANHYDROU Ingredient Name EWQ57Q8I5X) J) IDF5V39QO)		Basi	is of ngth MALEATE	Streng 20 mg

Product Characteristics					
Color	PINK (peach)	Score	2 pieces		
Shape	OVAL (convex)	Size	10mm		
Flavor		Imprint Code	707		
Contains					

P	Packaging						
#	ltem Code	Package Description	Marketing Start Date	Marketing End Date			
1	NDC:23155-773- 01	100 in 1 BOTTLE; Type 0: Not a Combination Product	10/01/2020				
2	NDC:23155-773- 05	500 in 1 BOTTLE; Type 0: Not a Combination Product	10/01/2020				
3	NDC:23155-773- 10	1000 in 1 BOTTLE; Type 0: Not a Combination Product	10/01/2020				
M	larketing	Information					

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA075479	10/01/2020	

Labeler - Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. (780779901)

Registrant - Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. (189630168)

Establishment

Name	Address	ID/FEI	Business Operations
Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc.		189630168	ANALYSIS(23155-704, 23155-705, 23155-706, 23155-707, 23155-772, 23155- 773), LABEL(23155-704, 23155-705, 23155-706, 23155-707, 23155-772, 23155-773), MANUFACTURE(23155-704, 23155-705, 23155-706, 23155-707, 23155-772, 23155-773), PACK(23155-704, 23155-705, 23155-706, 23155- 707, 23155-772, 23155-773)

Revised: 2/2024

Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.